



الاسم الرباعي للتدريسي بروفيسور رزگار مجيد



الدرجة الوظيفية: بروفيسور

اللقب العلمي: بروفيسور زائر

الكلية: الصيدلة

رقم الغرفة: G8

CONTACT

r.a.mageed@qmul.ac.uk



Tel +44(0)207-882-3989

<https://www.qmul.ac.uk/whri/people/academic-staff/items/mageedrizar.html>

تخرج رزگار مجيد من كلية الصيدلة في جامعة بغداد عام 1976. حصل على درجة الدكتوراه من كلية الطب بمستشفى لندن الملكي، جامعة لندن عام 1985. تم تعيينه زميلاً باحثاً في قسم علم المناعة في كلية الطب بجامعة برمنغهام عام 1984. حيث عمل حتى عام 1990 ثم انضم إلى معهد كينيدي للأمراض الروماتيزم كعالم. وفي عام 1996، تم تعيينه كأستاذ مساعد في جامعة امبيرال في لندن. في عام 2000 منح رزگار زمالة أبحاث التهاب المفاصل في المملكة المتحدة وتم تعيينه كأستاذ مساعد في مركز أمراض الروماتيزم في جامعة كوليج لندن. انضم رزگار إلى جامعة كوين ماري/لندن كبروفيسور في علم المناعة في مايو 2003. وفي عام 2009، أصبح رزگار زميلاً في الكلية الملكية لعلم الأمراض وفي عام 2014 حصل على زمالة الكلية الملكية للأطباء.

المجالات البحثية والبحوث المنشورة

1. Church MK, **Mageed RA**, Holgate ST. Human tonsillar mast cells: characteristics of histamine secretion and methods of dispersion. **Int Arch Allergy Appl Immunol** 1983; 72: 188-90.
2. Bourne JT, Kumar P, Huskisson EC, **Mageed RA**, Unsworth DJ, Wojtulewski JA. Arthritis and coeliac disease. **Ann Rheum Dis** 1985; 44: 592-8.
3. Kirk AP, O'Hara BP, **Mageed RA**, McMahon MS, McCarthy DS, Menashi S, Archer JR, Currey HLF. Pepsinogen-: an immunoglobulin binding artefact in "collagen" preparations. **Clin Exp Immunol** 1986; 65: 671-8.



4. **Mageed RA**, Dearlove M, Goodall DM, Jefferis R. Immunogenic and antigenic epitopes of immunoglobulins. XVII. Monoclonal antibodies reactive with common and restricted idiotopes on the heavy chain of human rheumatoid factor. **Rheumatol Int** 1986; **6**: 179-83.
5. **Mageed RA**, Walker MR, Jefferis R. Restricted light chain subgroup expression in human rheumatoid factor paraproteins determined by monoclonal antibodies. **Immunol** 1986; **59**: 473-8.
6. **Mageed RA**, Jefferis R. Molecular specificity and idiotype of human rheumatoid factors. **Monographs in Allergy** 1987; **22**: 24-30.
7. Newkirk MM, **Mageed RA**, Jefferis R, Chen PP, Capra JD. Complete amino acid sequences of variable regions of two human rheumatoid factors, BOR and KAS of the Wa idiotype family, reveal restricted use of heavy and light chain variable and joining region gene segments. **J Exp Med** 1987; **166**: 550-64.
8. Jose SA, Griffiths H, Lunec J, **Mageed RA**, Jefferis R. Immunogenic and antigenic epitopes of immunoglobulins. XX. Denaturation of human IgG3 by free radicals. **Mol Immunol** 1987; **24**: 1145-50.
9. Jones VE, Puttick AH, Williamson EA, **Mageed RA**. A new assay uses monoclonal anti-Rh (D) antibodies to determine rheumatoid factor specificity. I. Reactivity to a monoclonal antibody of the G3m (21) is more frequent in rheumatoid patients negative for G3m (21). **Clin Exp Immunol** 1988; **71**: 451-8.
10. Crowley JJ, Goldfien RD, Schrohenloher RE, Spiegelberg HL, **Mageed RA**, Jefferis R, Koopman WJ, Carson DA, Fong S. 1988. Incidence of two cross-reactive idiotype defines two mutually exclusive kappa light chain variable region subgroups for human rheumatoid factor paraproteins. **J Immunol** 1988; **140**: 3411-8.
11. Silverman GJ, Goldfien RD, Chen PP, **Mageed RA**, Jefferis R, Goni F, Frangione B, Fong S, Carson DA. Idiotype and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of auto antibodies in humans. **J Clin Invest** 1988; **82**: 469-75.
12. **Mageed RA**, Carson DA, Jefferis R. 1988. Analysis of rheumatoid factor autoantibodies in patients with essential mixed cryoglobulinaemia and rheumatoid arthritis. **Scand J Rheumatol** 1988; **S75**: 172-8.
13. **Mageed RA**, Carson DA, Jefferis R. Immunogenic and antigenic epitopes of immunoglobulins. XXIII. Idiotype and molecular specificity of human rheumatoid factors: analysis of cross-reactive idiotype of rheumatoid factor paraproteins from the Wa idiotype group in relation to their IgG subclass specificity. **Scand J Immunol** 1988; **28**: 233-40.
14. Jefferis R, **Mageed RA**. The epitope specificity and idiotype of monoclonal rheumatoid factors. **Scand J Rheumatol** 1988; **S75**: 89-92
15. Venables PJW, Baboonian C, Horsfall AC, Halliday D, Maini RN, Teo CG, **Mageed RA**, Millman G. The response to Epstein-Barr virus infection in Sjogren's syndrome. **J Autoimm** 1989; **2**: 439-48.
16. Shokri F, **Mageed RA**, Jefferis R, Kitas GD, Katsikis P, Moutsopoulos HM. Monoclonal anti-cross-reactive idiotype antibodies as possible probes for



lymphoproliferation in primary Sjogren's syndrome. **Br J Rheumatol** 1989; 28: 458-9.

17. Venables PJ, Baboonian C, Horsfall AC, Halliday D, Maini RN, Teo CG, **Mageed RA**, Millman G. The response of Epstein-Barr virus infection in Sjogren's syndrome. In: **Sjogren's syndrome a model for understanding autoimmunity**. Ed. N Talal; Academic Press Ltd. 1989; pp: 131.
18. Jefferis R, **Mageed RA**. The specificity and reactivity of rheumatoid factor with human IgG. **Monographs in Allergy** 1989; 26: 45-60.
19. Abderrazik M, Moynier M, Couret M, Combe B, **Mageed RA**, Jefferis R, Sany J, Brochier J. Frequency of rheumatoid factor-producing precursor B-cells in rheumatoid arthritis. Idiotypic studies. **Septime Symposium International D'Immuno-Rheumatologie**. Eds J Clot, J Sany, J Brochier. 1989; Pp: 143-7.
20. Crowley JJ, **Mageed RA**, Silverman GJ, Chen PP, Kozin F, Erger RA, Jefferis R, Carson DA. The incidence of a new human cross-reactive idiotype linked to subgroup V_HIII heavy chains. **Mol Immunol** 1990; 27: 87-94.
21. Shokri S, **Mageed RA**, Tunn E, Bacon PA, Jefferis R. Qualitative and quantitative expression of V_HI associated cross-reactive idiotopes within IgM rheumatoid factor from patients with early synovitis. **Ann Rheum Dis** 1990; 49: 150-4.
22. Kondratowicz GM, Symmons DPM, Bacon PA, **Mageed RA**, Jones EL. Rheumatoid lymphadenopathy: A morphological and immunohistochemical study. **J Clin Pathol** 1990; 43: 106-13.
23. Thompson KM, Randen I, Natvig JB, **Mageed RA**, Jefferis R, Carson DA, Tighe H, Forre Ö. Human monoclonal rheumatoid factors derived from the polyclonal repertoire of rheumatoid synovial tissue: incidence of cross-reactive idiotype and expression of V_H and V_L subgroups. **Eur J Immunol** 1990; 20: 863-8.
24. **R A Mageed**, D M Goodall, R Jefferis. 1990. A highly conserved conformational idiotope on human IgM rheumatoid factor paraproteins from the Wa cross-reactive idiotype family defined by a monoclonal antibody. **Rheumatol Int** 10: 57-63.
25. Brown CMS, Plater-Zyberk C, **Mageed RA**, Jefferis R, Maini RN. Analysis of immunoglobulins secreted by hybridomas derived from rheumatoid synovia; evidence for an oligoclonal B-cell response. **Clin Exp Immunol** 1990; 80: 366-72.
26. Lydyard PM, Quartey-Papafio RP, Broker BM, McKenzie L, Hay FC, Youinou PY, Jefferis R, **Mageed RA**. The antibody repertoire of early human B cells. III. Expression of cross-reactive idiotypes characteristic of certain rheumatoid factors and identifying V_kIII, V_HI, and V_HIII gene family products. **Scand J Immunol** 1990; 32: 709-16
27. Natvig JB, Randen I, Thompson K, Forre Ö, **Mageed RA**, Jefferis R, Carson DA, Tighe H, Pascual V, Victor KD, Capra JD. Probing of the rheumatoid factor (RF) V gene repertoire in rheumatoid arthritis (RA) by hybridoma clones. **Clin Exp Rheumatol** 1990; 6(S5): 75-80.



28. **Mageed RA**, Kirwan JR, Thompson PW, McCarthy DA, Holborow EJ. Characterisation of the size and composition of circulating immune complexes in patients with rheumatoid arthritis. **Ann Rheum Dis** 1991; 50: 231-236
29. MacKenzie LE, Youinou P, Hicks R, Yuksel B, **Mageed RA**, Lydyard PM. Auto and polyreactivity of IgM from CD5⁺ and CD5⁻ cord blood B-cells. **Scand J Immunol** 1991; 33: 329-35.
30. Deacon EM, Matthews JB, Potts AJC, Hamburger J, **Mageed RA**, Jefferis R. Expression of rheumatoid factor associated cross-reactive idiotopes by glandular B-cells in Sjogren's syndrome. **Clin Exp Immunol** 1991; 83: 280-5.
31. Shokri F, **Mageed RA**, Maziak BR, Jefferis R. Expression of V_HIII-associated cross-reactive idiotype on human B-lymphocytes. Association with staphylococcal protein A binding and staphylococcus aureus Cowan I stimulation. **J Immunol** 1991; 146: 936-40.
32. **Mageed RA**, Kirwan JR, Holborow EJ. Localisation of circulating immune complexes from patients with rheumatoid arthritis in murine spleen germinal centres. **Scand J Immunol** 1991; 34: 323-31.
33. Shokri F, **R A Mageed RA**, G D Kitas GD, P Katsikis P, H M Moutsopoulos HM, R Jefferis R. Quantitation of cross-reactive idiotype positive rheumatoid factor in autoimmune rheumatic diseases. An indicator of clonality and B-cell proliferative mechanisms. **Clin Exp Immunol** 1991; 85: 20-27.
34. **Mageed RA**, MacKenzie LE, Stevenson FK, Yuksel B, Shokri F, Maziak BR, Jefferis R, Lydyard PM. Selective expression of a V_HIV subfamily of immunoglobulin genes in human CD5⁺ B-lymphocytes from cord blood. **J Exp Med** 1991; 174: 109-13.
35. Silman AJ, Ollier W, **Mageed RA**. Rheumatoid factor production in the unaffected first degree relatives in multicase rheumatoid arthritis families. **J Rheumatol** 1991; 18: 512-5.
36. MacKenzie LE, **Mageed RA**, Youinou PY, Yuksel B, Jefferis R, Lydyard PM. Repertoire of CD5⁺ and CD5⁻ cord blood B-cells: Specificity and expression of V_HI and V_HIII associated idiotopes. **Clin Exp Immunol** 1992; 88: 107-11.
37. Abderrazik M, Moynier M, Jefferis R, **Mageed RA**, Combe B, Sany J, Brochier J. Analysis of monoclonal rheumatoid factors obtained from B cell repertoire in rheumatoid arthritis. **Scand J Immunol** 1992; 35: 149-57.
38. Lydyard PM, MacKenzie LE, Youinou PY, Deane M, Jefferis R, **Mageed RA**. Specificity and idiotype expression of IgM produced by CD5⁺ and CD5⁻ cord blood B-cell clones. **Ann NY Acad Sci** 1992; 651: 527-39.
39. Mierau R, Gause A, Kuppers R, Michels M, **Mageed RA**, Jefferis R, Genth E. A human monoclonal IgA rheumatoid factor using the V_kIV light chain gene. **Rheumatol Int** 1992; 12: 23-31.



40. Newkirk MM, Rauch J, **Mageed RA**, Jefferis R, Posnett DN, Silverman GJ. Restricted immunoglobulin variable region gene usage by hybridoma rheumatoid factors from patients with systemic lupus erythematosus and rheumatoid arthritis. **Mol Immunol** 1993; 30: 255-63.
41. Shokri F, **Mageed RA**, Maziak BR, Talal N, Amos N, Williams B, Jefferis R. Lymphoproliferation in primary Sjogren's syndrome: evidence for selective expansion of a B-cell subset characterised by the expression of cross-reactive idiotype (CRI). **Arthritis Rheum** 1993; 36: 1128-36.
42. Shokri F, **Mageed RA**, Richardson P, Jefferis R. High frequency expression and modulation of autoantibody associated cross-reactive idiotypes in CD5 expressing B-lymphocytes from patients with chronic lymphocytic leukaemia. **Scand J Immunol** 1993; 37: 673-9.
43. Deane M, MacKenzie LE, Stevenson F, Youinou PY, Lydyard PM, **Mageed RA**. The genetic basis of human V_H4 gene family-associated cross reactive idiotype expression in CD5⁺ and CD⁻ cord blood B-lymphocyte clones. **Scand J Immunol** 1993; 38: 348-58.
44. Scott BB, Sadigh S, Stow M, **Mageed RA**, Andrew EM, Maini RN. Molecular mechanisms involved in pathogenic anti-mouse red blood cell antibodies (MRBC) in NZB mice. **Clin Exp Immunol** 1993; 93: 26-33.
45. Scott BB, Sadigh S, Stow M, **Mageed RA**, Andrew EM, Maini RN. Anti-mouse red blood cell monoclonal antibodies use functionally rearranged genes from the V_H J558 family and are derived from the CD5 negative B-lymphocyte subpopulation. **Immunol** 1993; 79: 568-73.
46. Shokri F, **Mageed RA**, Jefferis R. A quantitative ELISA for the measurement of rheumatoid factor associated cross-reactive idiotype in serum from patients with rheumatic diseases. **Br J Rheumatol** 1993; 32: 862-9.
47. Lydyard PM, Lamour A, MacKenzie LE, Jamin C, **Mageed RA**, Youinou P. CD5⁺ B cells and the immune system. **Immunol Lett** 1993; 38: 159-66.
48. Shokri F, **Mageed RA**, Richardson P, Jefferis R. Immunophenotypic and idiotypic characterisation of leukaemic B-cells from patients with prolymphocytic leukaemia: Evidence for a selective expression of immunoglobulin variable region (IgV) gene products. **Leukaemia Res** 1993; 17: 669-76.
49. Youinou P, MacKenzie LE, Lamour A, **Mageed RA**, Lydyard PM. Human CD5-positive B cells in lymphoid malignancy and connective tissue disease. **Eur J Clin Invest** 1993; 23: 139-50.
50. Sadigh S, Scott BB, **Mageed RA**, Malcolm A, Andrew EM, Maini RN. Identification of hybridomas derived from mouse CD5⁺ B-lymphocytes by fluorescent staining for cytoplasmic CD5 expression. **Immunol** 1994; 81: 558-63.
51. **Mageed RA**. The RF antigen. In: **Manual of Biological Markers of Disease**. Eds.: WJ van Venrooij and RN Maini. Dordrecht: Kluwer Academic Publishers, The Netherlands; 1994.



52. Moazzzeni M, Mosayebi G, Stevenson FK, Rowe M, Abbot S, **Mageed RA**, Shokri F. Biased utilisation of immunoglobulin variable region heavy and light chain genes by the malignant CD5-negative B-lymphocytes from patients with Burkitt's lymphoma. **Int J Cancer** 1994; 58: 226-32.
53. Scott BB, Sadigh S, Andrew EM, Maini RN, **Mageed RA**. Affinity maturation and isotype switch in clonally related anti-erythrocyte autoantibodies. **Scand J Immunol** 1994; 40: 16-21.
54. **R A Mageed RA**, J Vencovsky J, R N Maini RN. Rheumatoid factors and germline genes in rheumatoid arthritis: evidence of an intrinsic B-lymphocyte defect? **Br J Rheumatol** 1994; 33: 105-7.
55. Suleyman S, Thompson KM, Sioud M, Randen I, **Mageed RA**, Natvig JB. Monoclonal antibodies against products of two distinct human V_H3 genes expressed in the early repertoire. **Scand J Immunol** 1994; 40: 681-90.
56. Vencovsky J, **Mageed RA**, Ollier WE, Maini RN. Monozygotic rheumatoid arthritis twin pairs express similar levels of conserved immunoglobulin V genes in polyclonal rheumatoid factors irrespective of disease status. **Scand J Immunol** 1995; 42: 147-157.
57. Brown CM, Fitzgerald KJ, Moyes S, **Mageed RA**, Williams DG, Maini RN. Sequence analysis of immunoglobulin heavy chain variable region genes from the synovium of a rheumatoid arthritis patient shows little evidence of mutation but diverse CDR3. **Immunol** 1995; 84: 367-74.
58. MacGregor AJ, Bamber S, Carthy D, Vencovsky J, **Mageed RA**, Ollier WER, Silman AJ. Heterogeneity of Disease phenotype in monozygotic twins concordant for rheumatoid arthritis. **Br J Rheumatol** 1995; 34: 215-20.
59. MacGregor AJ, Ollier WER, Vencovsky J, **Mageed RA**, Carthy D, Silman AJ. Rheumatoid factor isotypes in monozygotic and dizygotic twins discordant for rheumatoid arthritis. **J Rheumatol** 1995; 22: 2203-7.
60. Harmer IJ, **Mageed RA**, Kaminsky A, Charles P, Bruggemann M, Mackworth-Young C. Chimaeric monoclonal antibodies encoded by the human VH26 gene from naive transgenic mice display a wide range of antigen binding specificities determined. Using chimaeric antibodies from naive transgenic mice. **Immunol** 1996; 88: 174-82.
61. Moyes S, Brown C, Scott BB, Maini RN, **Mageed RA**. Analysis of V_K genes in RA synovial B-lymphocytes provides evidence for both, polyclonal activation and antigen-driven selection. **Clin Exp Immunol** 1996; 105: 89-98.
62. de S Oliveira GG, Izui S, Ravirajan CT, **Mageed RA**, Lydyard PM, Elson CJ, Barker RN. Antigen specificity of red blood cell-reactive monoclonal antibodies from NZB mice. **Clin Exp Immunol** 1996; 105: 313-20.
63. **Mageed RA**, B rretzen M, Moyes SP, Thompson KM, Natvig JB. Rheumatoid factor autoantibodies in health and disease. **Ann NY Acad Sci** 1997; 815: 296-311.



64. **Mageed RA**, Moyes SP, Vencovsky J, Maini RN. Somatic mutation and CDR3 length of immunoglobulin lambda variable region genes in the synovium of patients with rheumatoid arthritis. **Ann NY Acad Sci** 1997; **815**: 319-23.
65. Vencovsky J, Maini RN, Ollier WE, **Mageed RA**. Immunoglobulin variable region gene expression in rheumatoid factors in monozygotic twins with rheumatoid arthritis. **Ann NY Acad Sci** 1997; **815**: 324-6.
66. **Mageed RA**, S P Moyes SP, K M Thompson KM, J B Natvig JB. 1997. Molecular and cellular aspects of human rheumatoid factor production and idiotypes. In **Human Idiotypes in Medicine: Autoimmunity, Infection and Cancer**. Editors: Y Shoenfeld, RC Kennedy, S Ferrone; Elsevier Science. 1997; P: 135-155
67. **Mageed RA**, Adams G, Podhajcer O, Chernajovsky Y. Prevention of collagen-induced arthritis model in mice by gene delivery of soluble p75 tumour necrosis factor receptor. **Gene Therapy** 1998; **5**: 1584-92.
68. Hajeer AH, Iazarus M, Turner D, **Mageed RA**, Vencovsky J, Huchinson I, Ollier WE. Functional polymorphisms in the IL-10 promoter region are associated with IgA rheumatoid factor in rheumatoid arthritis. **Scand J Rheumatol** 1998; **27**: 142-5.
69. Annekov A, Moyes SP, Eshhar Z, **Mageed RA**, Chernajovsky Y. Loss of original antigenic specificity in T cells to collagen by transduction with a chimeric receptor containing single chain anti-collagen antibody and FcγRIε subunit. **J Immunol** 1998; **161**: 6604-13.
70. Melero J, Aguilera I, **Mageed RA**, Jefferis R, Tarragó D, Núñez-Roldán A, Sánchez B. The frequent expansion of a subpopulation of B cells that express RF-associated cross-reactive idiotypes: evidence from analysis of a panel autoreactive monoclonal antibodies. **Scand J Immunol** 1998; **48**: 152-8.
71. Moyes SP, Maini RN, **Mageed RA**. Differential use of immunoglobulin light chain genes and B lymphocyte expansion at sites of disease in rheumatoid arthritis (RA) compared with circulating B lymphocytes. **Clin Exp Immunol** 1998; **113**: 276-88.
72. Chernajovsky Y, Annekov A, Herman C, Triantaphylopoulos K, Gould D, Draja H, Moyes SP, Croxford JL, **Mageed RA**, Podhajcer O, Baker D. Gene therapy for rheumatoid arthritis: Theoretical considerations. **Drugs and Ageing** 1998; **12**: 29-41
73. Abadi J, Friedman J, **Mageed RA**, Jefferis R, Rodriguez-Barradas M, Pirofski L-A. Human antibodies elicited by a 23-valent pneumococcal polysaccharide vaccine express idiotypic determinants indicative of V_H3 gene segment usage. **J Infect Dis** 1998; **178**: 707-16.
74. Mason AN, Harmer I, **Mageed RA**, Mackworth-Young CG. The BH1 idotype defines a population of anticardiolipin antibodies closely associated with the antiphospholipid syndrome. **Lupus** 1999; **8**: 234-9.



75. Potter KN, Li Y, **Mageed RA**, Jefferis R, Capra JD. Anti-idiotypic antibody D12 and superantigen SPA both interact with human VH3-encoded antibodies on the external face of the heavy chain involving FR1, CDR2 and FR3. **Mol Immunol** 1999; 35: 1179-87.
76. Potter KN, Li Y, **Mageed RA**, Jefferis R, Capra JD. Molecular characterisation of VH1 specific variable region determinant recognized by anti-idiotypic monoclonal antibodies G6 and G8. **Scand J Immunol** 1999; 50: 14-20.
77. Axford JS, Rees DH, **Mageed RA**, Wordsworth P, Alavi A, Steere A. Increased IgA rheumatoid factor and VH1-associated cross-reactive idiotype expression in patients with Lyme arthritis and neuroborreliosis. **Ann Rheum Dis** 1999; 58:757-61.
78. Williams DG, Moyes S, **Mageed RA**. Rheumatoid factor isotype switch and somatic mutation variants within rheumatoid arthritis synovium. **Immunol** 1999; 98: 123-36.
79. **Mageed RA**, Vencovsky J, Youinou P, Lydyard PM. Polyreactivity and immunoglobulin variable region gene usage in human CD5+ B cells. **Trans Cauc J Immunol** 1999; 1: 15-24.
80. Chernajovsky Y, Dreja H, Daly G, Annenkov A, Gould D, Adams G, Croxford LJ, Baker D, Podhajcer OL, **Mageed RA**. Immuno and genetic therapy in autoimmune diseases. **Genes and Immunity** 2000; 1: 295-307.
81. Suleyman S, Thompson K, **Mageed RA**, Natvig JB. Molecular analysis of idiotopes recognized by anti-VH3 antibodies 7B4, B6 and D12. Human immunoglobulin CDR2 sequences are mimicked by HIV gp120. **Scand J Immunol** 2000; 52: 341-7.
82. Lattesjö H, Burd GP, **Mageed RA**. CD4⁺ T lymphocytes with constitutive CD40 ligand in pre-autoimmune (NZB x NZW) F1 lupus-prone mice: phenotype and role in autoreactivity. **J Immunol** 2000; 165: 4095-104.
83. Gharagozloo S, Sharifian RA, Stevenson FK, Jefferis R, **Mageed RA**, Shokri F. 2000. Analysis of the expressed immunoglobulin variable region heavy chain gene products in paraproteins from Iranian patients with multiple myeloma. **Pathol Oncol Res** 2000; 6: 185-90.
84. **Mageed RA**, Harmer IJ, Moyes SP, Wynn S, Brüggemann M, Mackworth-Young CG. Rearrangement of the human heavy chain variable region gene V3-23 generates polyreactive antibodies in transgenic mice. **Clin Exp Immunol** 2001; 123: 1-8.
85. Mason AN, **Mageed RA**, Mackworth-Young CG. The effects of a human IgM monoclonal anticardiolipin antibody on pregnancy in a transgenic mouse model. **Lupus** 2001; 10: 289-94
86. Porakishvili N, **Mageed R**, Jamin C, Pers JO, Kulikova N, Renaudineau Y, Lydyard PM, Youinou P. Recent progress in the understanding of B-cell functions in autoimmunity. **Scand J Immunol** 2001; 54: 30-8
87. Vencovsky J, Jarosova K, Ruzickova S, Nemcova D, Niederlova J, Ozen S, Alikasifoglu M, Bakkaloglu A, Ollier WE, **Mageed RA**. Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. **Arthritis Rheum** 2001; 44: 2387-91.



88. Vencovsky J, Zďárský E, Moyes SP, Hajeer A, Ruzicková Š, Cimburek Z, Ollier WE, Maini RN, **Mageed RA**. Polymorphism in the immunoglobulin VH gene V1-69 affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope. **Rheumatology** 2002; **41**:401-10.
89. Youinou P, Lydyard PM, **Mageed RA**. B cells underpin lupus immunopathology. **Lupus** 2002; **11**: 1-3.
90. **Mageed RA**, Zack D. The target antigen and pathology of anti-DNA autoantibodies in systemic lupus erythematosus. **Lupus** 2002; **11**: 783-6.
91. **Mageed RA**, Isenberg DA. Tumour necrosis factor alpha (TNF α) and anti-TNF α in autoimmune rheumatic diseases and role in the induction of anti-DNA autoantibodies. **Lupus** 2002; **11**: 850-5.
92. Jury EC, Kabouridis PS, Abba A, **Mageed RA**, Isenberg DA. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic Lupus erythematosus. **Arthritis Rheum** 2003; **48**:1343-54.
93. **Mageed RA**, Prud'homme GJ. Immunopathology and the gene therapy of lupus. **Gene Ther** 2003; **10**: 861-74.
94. [Mackworth-Young CG](#), [Harmer IJ](#), [Mageed RA](#). The role of antigen in the selection of the human V3-23 immunoglobulin heavy chain variable region gene. **Clin Exp Immunol** 2003; **134**: 420-5.
95. Jury EC, Kabouridis PS, Flores-Borja F, **Mageed RA**, Isenberg DA. Altered lipid raft-associated signalling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. **J Clin Invest** 2004; **113**: 1176-87.
96. Renaudineau Y, Hillion S, Saraux A, ***Mageed RA**, *Youinou P. An alternative exon 1 of the cd5 gene regulates CD5 expression in human B lymphocytes. **Blood** 2005; **106**: 2781-9. *(Joint last authorship)
97. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, **Mageed RA**. Decreased Lyn expression and translocation to lipid raft signalling domains in B-lymphocytes from patients with systemic lupus erythematosus. **Arthritis Rheum** 2005; **52**: 3955-65.
98. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, **Mageed RA**. Lyn deficiency in B cells from patients with systemic lupus erythematosus: **Arthritis Rheum** 2006; **54**: 2037-8.
99. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, **Mageed RA**. Altered lipid raft-associated proximal signalling and translocation of CD45 tyrosine phosphatase in B-lymphocyte from patients with lupus disease. **Arthritis Rheum** 2007; **56**: 291-302.



100. Taher TE, Tulone C, Fatah R, D'Acquisto F, Gould DJ, **Mageed RA**. Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors. **Gene Ther** 2008; **15**: 998-1006.

101. Zouali M, **Mageed RA**. Cellular interactions and signalling defects in lupus. **Lupus** 2008; **17**: 236-40.

102. Youinou P, Taher TE, Mankai A, Berthou C, **Mageed RA**. Anti-CD20 in targeting B-lymphocytes for the treatment of autoimmune diseases. Clinical benefits and insights into the role of B-lymphocytes in disease pathology.

Immunol Endocrine Metabol Agents Med Chem 2008; **8**:222-34.

103. **Mageed RA**. New strategies and biological agents in the treatment of autoimmune inflammatory diseases. Progress and challenges. **Immunol Endocrine Metabol Agents Med Chem**, 2008, **8**: 191-9.

104. Habib HM, Taher TE, DA Isenberg DA, **RA Mageed RA**. Enhanced tumor necrosis factor alpha-mediated apoptosis of T-lymphocyte in patients with systemic lupus erythematosus. **Scand J Rheumatol** 2009, **38**: 112-20.

105. Rochas C, Hillion S, Saraux A, **Mageed RA**, Youinou P, Jamin C, Valérie Devauchelle V. Transmembrane BAFF from rheumatoid synoviocytes requires IL-6 to induce the expression of RAG in B lymphocytes. **Arthritis Rheum** 2009, **60**: 1261-71.

106. Alard J-E, Dueymes M, **Mageed RA**, Saraux A, Youinou P, Jamin C. CCR5 in association with HSP70 promotes apoptosis induced by anti-HSP60 antibody.

FASEB J 2009; **23**: 2772-9.

107. Garaud S, Le Dantec C, Jousse-Joulin S, Hanrotel-Saliou C, Saraux A, **Mageed RA**, Youinou P, Renaudineau Y. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. **J Immunol** 2009 ; **182**: 5623-32.

108. Youinou P, Taher TE, **Mageed RA**, Renaudineau Y. B-lymphocyte cytokines in autoimmune diseases. **Arthritis Rheum** 2009; **60**: 1873-80.

109. Garaud S, Le Dantec C, de Mendoza AR, **Mageed RA**, Youinou P, Renaudineau Y. IL-10 production by B cells expressing CD5 with the alternative exon 1B.

Ann NY Acad of Sci 2009; **1173**: 280-5.

110. Taher TE, Parikh K, Flores-Borja F, Mletzko S, Isenberg DA, Maikel P. Peppelenbosch MP, **Mageed RA**. Protein phosphorylation and kinome profiling reveal altered regulation of multiple signalling pathways in B lymphocytes from patients with systemic lupus erythematosus. **Arthritis Rheum** 2010; **62**: 2412-23.

111. Seité J-F, Cornec D, Renaudineau Y, Youinou P, **Mageed RA**, Hillion S. Intravenous immunoglobulin promotes apoptosis of mature human B



lymphocytes by using CD22 to modulate their antigen receptor. **Blood** **2010; 116: 1698-704.**

112. **Mageed RA**, Taher TE, Jawad AS. Disease mechanisms, genetic susceptibility and therapeutic approaches in lupus disease. **In Gene Therapy for Autoimmune and Inflammatory Diseases; Editors: Paul Robbins and Yuti Chernajovsky; Springer (Basel); pp 127-146; 2010**
113. Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, Berthou C, **Mageed RA**, Renaudineau Y, Youinou P. CD5 Promotes IL-10 Production in Chronic Lymphocytic Leukemia B Cells through STAT3 and NFAT2 Activation. **J Immunol** **2011; 186: 4835-44.**
114. **Mageed RA**, Garaud S, Taher TE, Parikh K, Pers JO, Jamin C, Renaudineau Y, Youinou P CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte. **Autoimmun Rev** **2012; 11:795-8.**
115. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, Jawad A, Pathan E, Kinderlerer A, Taylor PC, Williams R, **Mageed R.** Incomplete response of inflammatory arthritis to TNF α blockade is associated with the Th17 pathway. **Ann Rheum Dis** **2012; 71:1741-8.**
116. Thabet Y, Cañas F, Ghedira I, Youinou P, **Mageed RA**, Renaudineau Y. Altered patterns of epigenetic changes in systemic lupus erythematosus and auto-antibody production: Is there a link? **J Autoimmun** **2012; 39: 154-60.**
117. Bystrom J, Al-Adhoubi N, Al-Bogami M, Jawad AS, Mageed RA. Th17 lymphocytes in respiratory syncytial virus infection. **Viruses** **2013; 5:777-91.**
118. Taher TE, Muhammad HA, Rahim A, Flores-Borja F, Renaudineau Y, Isenberg DA, **Mageed RA.** Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets. **Eur J Clin Invest** **2013; 43:866-80.**
119. Taher TE, Muhammad HA, Bariller E, Flores-Borja F, Renaudineau Y, Isenberg DA, **Mageed RA.** B-lymphocyte signalling abnormalities and lupus immunopathology. **Int Rev Immunol** **2013; 32(4):428-44.**
120. Albogami MM, Jawad AS, **Mageed RA.** Bone loss in osteoporosis and arthritis. Pathogenesis and therapeutic strategies. **Saudi Med J** **2014; 35: 224-33.**
121. Bystrom J, Taher TE, Muhyaddin MS, Clanchy F, Mangat P, Jawad AS, Williams RO, **Mageed RA.** Harnessing the therapeutic potential of Th17 cells. **Mediators Inflamm** **2015; 2015: 205156.**
122. Al-Bogami M, Alkhorayef M, Bystrom B, Akanle OA, Al-Adhoubi N, Jawad AS, **Mageed RA.** Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate. **Saudi Med J** **2015 ; 36: 1305-11.**



123. Simon Q, Jacques-Olivier Pers J-O, Cornec D, **Mageed RA**, Hillion S. In-depth characterization of CD24^{high}CD38^{high} transitional human B cells reveals different regulatory profiles. **J Allergy Clin Immunol** 2016; 137: 1577-1584.e10.
124. Taher TE, Bystrom J, Ong VH, Isenberg DA, Renaudineau Y, Abraham DJ, **Mageed RA**. Intracellular B lymphocyte signalling and the regulation of humoral immunity and autoimmunity. **Clin Rev Allergy Immunol**. 2017; 53: 237-264.
125. Bystrom J, Clanchy FI, Taher TE, Al-Bogami MM, Muhammad HA, Alzabin S, Mangat P, Jawad AS, Williams RO, **Mageed RA**. Response to treatment with TNF α inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF⁺ T lymphocytes. **Clin Rev Allergy Immunol**. 2017; 53: 265-276.
126. Bystrom J, Clanchy FI, Taher TE, Mangat P, Jawad AS, Williams RO, **Mageed RA**. TNF α in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases. **Cytokine** 2018; 101: 4-13.
127. Garaud S, Taher TE, Debant M, Burgos M, Melayah S, Berthou C, Parikh K, Pers JO, Luque-Paz D, Chiocchia G, Peppelenbosch M, Isenberg DA, Youinou P, Mignen O, Renaudineau Y, **Mageed RA**. CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. **Cell Mol Immunol**. 2018;15:158-170.
128. Taher TE, Ong VH, Bystrom J, Hillion S, Simon Q, Denton CP, Pers JO, Abraham DJ, **Mageed RA**. Defective regulation of autoreactive IL-6 producing transitional B lymphocytes in patients with systemic sclerosis. **Arthritis Rheumatol** 2018 Mar;70(3):450-461.
129. Bystrom J, Clanchy FIL, Taher TE, Al-Bogami M, Ong VH, Abraham DJ, Williams RO, **Mageed RA**. Functional and phenotypic heterogeneity of Th17 cells in health and disease. **Eur J Clin Invest**. 2019 Jan;49(1):e13032.
130. Taher TE, Bystrom J, Mignen O, Pers J-O, Renaudineau Y, **Mageed RA**. CD5 and B lymphocyte responses: multifaceted effects through multitudes of pathways and channels. **Cell Mol Immunol**. 2020 Nov;17(11):1201-1203. doi: 10.1038/s41423-020-0490-z.
131. Bystrom J, Taher TE, **Mageed RA**. Metabolic pathways underpinning lymphocyte differentiation and responses in health and disease. **Immunometabolism**. 2020;2(3):e200024. <https://doi.org/10.20900/immunometab20200024>.
132. Al-Bogami M, Bystrom J, Clanchy FIL, Taher TE, Mangat P, Williams RO, Jawad AS, **Mageed RA**. TNF α inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20. **Rheumatology (Oxford)**. 2021 Feb 1;60(2):947-957. doi: 10.1093/rheumatology/keaa551.
133. Clanchy FIL, Borghese F, Bystrom J, Balog A, Penn H, Hull DN., Wells GMA, Kiriakidis S, Taylor PC, Sacre SM, Williams LM, Stone TW, **Mageed RA***, Williams RO*. TLR expression profiles are a function of disease status



in Rheumatoid Arthritis and experimental arthritis. **J Autoimmun** 2021 Mar; 118:102597. doi: 10.1016/j.jaut.2021.102597. *Joint senior authors.

134. Clanchy FIL, Borghese F, Bystrom J, Balog A, Penn H, Taylor PC, Stone TW, **Mageed RA***, Williams RO*. Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expression. **J Autoimmun.** 2022 Apr; 128:102810. doi: 10.1016/j.jaut.2022.102810. *Joint senior authors.
135. Bystrom J, Taher TE, Henson S, Gould DJ, Rizgar A. **Mageed RA**. Metabolic requirements of Th17 cells and of B cells: Regulation and defects in health and in inflammatory diseases. **Front Immunol.** 2022 Oct;13:990794. doi: 10.3389/fimmu.2022.990794.
136. Beesley CF, Goldman NR, Taher TE, Denton CP, Abraham DJ, **Mageed RA***, Ong VH*. Dysregulated B cell function and disease pathogenesis in systemic sclerosis. *Frontiers in Immunol* (Submitted). **Front Immunol.** 2023 Jan; 13:999008. doi: 10.3389/fimmu.2022.999008. *Joint senior authors.
137. Al-Bogami MM, Akanle OA, Aldawood S, Alkhorayef M, Sulieman A, Jawad AS, **Mageed RA**. Comparison of bone mineral density changes between male and female osteoporosis patients using dual energy X-ray absorptiometry scan. **Appl Radiat Isot.** 2023 Apr;194:110624. doi: 10.1016/j.apradiso.2022.110624.
138. Clanchy FIL, Borghese F, Bystrom J, Balog A, Penn H, Hull DN, Mageed RA, Taylor PC, Williams RO. Endotoxin tolerance-associated mechanisms are 1 modulated by the TNF blockade response. **J Autoimmun** (Submitted, Mar 2024).
139. Beesley C, Cole A, Goldman N, Odewale O, Barnett J, Abraham D, Denton C, **Mageed RA***, Ong V*. Complement perturbation in scleroderma-related interstitial lung disease with emphysema. (Invited Review by the journal **Best Practice and Research Clinical Rheumatology**; in preparation). *Joint senior authorship.
140. Goldman N, Tynan A, Shah S1, Beesley C, **Mageed RA**, Denton C, Ong V. Rituximab and tocilizumab and their effect on lung disease progression in scleroderma. A retrospective cohort study at a single centre. (In preparation).
141. Beesley C, Goldman N, Cubuk C, Lewis M, Abraham DA, Denton C, Mageed RA*, Ong V*. Paired transcriptomic analysis of transitional B cells identifies four distinct subsets and reveals the basis of defective peripheral tolerance in systemic sclerosis. (In preparation) *Joint senior authors.
142. Muhammad HA, Taher TE, Mullen L, Pastan IH, Chernajovsky Y, Gould DJ, **Mageed RA**. Modulation of B lymphocyte responses by targeted delivery of siRNA through CD22. (In preparation).
143. Taher TE, Beesley CF, Bystrom J, Goldman NR, Abraham DJ, Ong VH, **Mageed RA**. B lymphocyte signalling: gyratory pathways and intricate controls, in health and subtle flaws in disease. **Frontiers in Immunol** (Invited submission).



144. Mletzko S, Taher TE, Duchene J, Varin M-M, Fabian Flores Borja F, Warnes G, Yuti Chernajovsky Y, Isenberg DA, **Mageed RA**. A subset of autoreactive B lymphocytes expressing low CD45RB is selectively expanded in patients with lupus. **(In preparation)**.
145. Taher TE, Warnes G, El Shikh ME, Isenberg DA, **Mageed RA**. Altered CD45RB expression and enhanced PI3k δ phosphorylation underlies dysregulated B lymphocyte function in patients with lupus. **(In preparation)**.
146. Nordin NI, Cooper D, D'Acquisto F, Gibbons S, Perrett D, **Mageed RA**. 6-shogaol inhibits production of iNOS, IL-2, IL-23, IL-20 and IL-8, reduces infiltration of PMN and modulates keratinocyte responses in psoriasis. **(In preparation)**.
147. Bystrom J, Taher TE, Nordin NI, Rahim A, Jawad AS, **Mageed RA**. The effect of tumour necrosis factor alpha on autoimmunity in lupus disease. **(In preparation)**.
148. Taher TE, Gould D, D'Acquisto F, **Mageed RA**. Inhibition of NF-KB by a nemo-binding domain peptide promotes B-lymphocyte death and exacerbates murine lupus disease in vivo **(In preparation)**.

National and International Conference Publications:

149. Kirk AP, **Mageed RA**, Archer JR, Currey HLF. Binding of rheumatoid sera to cartilage extracts. **Br J Rheumatol 1984; 23: 136**.
150. Bourne JT, Huskisson EC, Kumar P, **Mageed R**, Wojtulewski JA. Arthritis and coeliac disease. **Br J Rheumatol 23: 147**.
151. Kirk AP, O'Hara B, McMullin J, **Mageed RA**, Menashi S, Archer JR, Currey HLF. An aggregate binding factor in cartilage. **Br J Rheumatol 1985; 24: 97**.
152. Jefferis R, Jose S, **Mageed RA**, Griffiths HR, Lunec J. Free radical induced denaturation of human IgG. **Clin Rheumatol 1987; S6: 117**.
153. **Mageed RA**, Jefferis R. Analysis of rheumatoid factor idiotypy in relation to molecular specificity. **Clin Rheumatol 1987; S6: 135**
154. **Mageed RA**, Tunn EJ, Shokri F, Bacon PA, Jefferis R. Structural analysis of rheumatoid factor in an early synovitis clinic. **Br J Rheumatol 1987; S25: 35**.
155. Jefferis R, **Mageed RA**. 1987. Epitope specificity and idiotypy of rheumatoid factors. **Scand J Rheumatol 1987; S68: 9**.
156. **Mageed RA**, Jefferis R. Structural analysis of rheumatoid factors in essential mixed cryoglobulinaemia (EMC) and rheumatoid arthritis (RA). **Scan J Rheumatol 1987; S68: 13**.
157. Crowley JJ, **Mageed RA**, Silverman GJ, Jefferis R, Chen PP, Carson DA. Structural and genetic analysis of a new cross-reactive idiotypy (CRI) associated with human rheumatoid factor heavy chains. **Arthritis Rheum 1988; S31: 47**.



158. **Mageed RA**, Tunn EJ, Shokri S, Bacon PA, Jefferis R. Structural analysis of rheumatoid factor in an early synovitis clinic. **Br J Rheumatol** 1987; 25: 35.
159. **Mageed RA**, Jefferis R. Analysis of immunoglobulin variable region gene usage in rheumatoid factors: possible relationship to genetic predisposition in rheumatoid arthritis. Workshop proceedings. **Disease Markers** 1987; 6: 57
160. **Mageed RA**, Tunn E, Bacon PA, Jefferis R. IgG subclass specificity of IgM rheumatoid factors in early synovitis clinic patients. **Br J Rheumatol** 1988; (suppl 1) 27: 35.
161. **Mageed RA**, R Jefferis R. The major human RF cross-reactive idiotype require heavy and light chain as well as conformational idiotopes. **Br J Rheumatol** 1988; (suppl 1) 27: 36
162. Shokri F, **Mageed RA**, Holder R, Jefferis R. A quantitative ELISA for germline encoded RF in RA patients. **Br J Rheumatol** 1988; (suppl 1) 27: 36.
163. Shokri F, Tunn E, **Mageed RA**, Bacon PA, Jefferis R. Quantitative and qualitative evaluation of IgM-RF in RA and associated clinical subsets. **Br J Rheumatol** 1988; (suppl 1) 27: 56.
164. **Mageed RA**, Jefferis R. Rheumatoid factors and staphylococcal protein A have an apparently common binding specificity for human IgG. **Br J Rheumatol** 1988; (suppl) 27: 58.
165. Tunn E, Salmon M, **Mageed R**, P A Bacon PA. Remission in early rheumatoid arthritis. **Br J Rheumatol** 1988; (suppl) 27: 62.
166. Plater-Zyberk C, Brown CMS, Johnson JW, Maini RN, **Mageed RA**, Jefferis R. Hybridomas from rheumatoid synovium express CD5 antigen and show restricted gene usage. **Br J Rheumatol** 1988; (suppl 2) 27: 120.
167. **Mageed RA**, Kirwan JR, Thompson P, McCarthy DA, Holborow EJ. Size and composition of circulating immune complexes (CICs) in articular and extraarticular rheumatoid arthritis. **Br J Rheumatol** 1988; (suppl 2) 27: 54.
168. **Mageed RA**, Kirwan JR, Holborow EJ. Localisation of circulating immune complexes from patients with rheumatoid arthritis in murine spleen germinal centres. **Br J Rheumatol** 1988; (suppl 2) 27: 53.
169. **Mageed RA**, Jefferis R. 1988. Rheumatoid factors and staphylococcal protein A have an apparently common binding specificity for human IgG. **Br J Rheumatol** 1988; (suppl) 27: 58.2
170. Shokri F, **Mageed RA**, Kitas GD, Moutsopoulos HM, Jefferis R. The level of rheumatoid factor-associated cross-reactive idiotopes in Sjogren's syndrome, rheumatoid arthritis, systemic lupus erythematosus and healthy individuals. **Br J Rheumatol** 1989; (suppl 1) 28: 40.
171. Silman AJ, **Mageed R**, Ollier WER. Class specific rheumatoid factors in first degree relatives of probands with rheumatoid arthritis. **Br J Rheumatol** 1989; (suppl 2) 28: 24.



172. Kondratowicz G, **Mageed RA**, Bryant FJ, Jefferis R, Plewes PL. A quantitative immunohistological study of plasma cells producing germlinePL gene encoded RF in rheumatoid and osteoarthritic synovia. **Br J Rheumatol 1990; (suppl 1) 29: 13.**
173. Natvig JB, Pascual V, Victor KD, Randen I, Thompson K, Forre O, Capra JD, **Mageed RA**, Jefferis R, Carson DA, Tighe H. Probing the rheumatoid factor (RF) V gene repertoire in rheumatoid arthritis (RA) by hybridoma clones. **Scand J Immunol 1990; 32: 408.**
174. Plater-Zyberk C, Brown CMS, **Mageed RA**, Maini RN. B-cell hybridomas derived from rheumatoid synovium express CD5 antigen and cross-reactive idiotype. **Clin Rheumatol 1990; 9: 580.**
175. Shokri F, Mageed RA, Jefferis R. Selective stimulation of different subsets of B-cells by SAC and EBV as evidenced by the expression of cross-reactive idiotype. **Scand J Immunol 1990; 32: 414.**
176. Shokri F, **Mageed RA**, Maziak R, Talal N, Moutsopoulos H, Williams BD, Jefferis R. Lymphoproliferation in primary Sjogren's syndrome: evidence for selective expansion of a B-cell subset characterised by the expression of cross-reactive idiotypes. **Clin Exp Rheumatol 1990; (S-5) 8: 99.**
177. Deacon EM, Matthews JB, Potts AJB, Hamburger J, **Mageed RA**, Jefferis R. Expression of cross-reactive idiotypes on rheumatoid factors by glandular B-cells in Sjogren's syndrome. **Clin Exp Rheumatol 1990; (S-5) 8: 98.**
178. MacKenzie LE, **Mageed RA**, Youinou PY, Hicks R, Jefferis R, Lydyard PM. Auto antibody specificity and idiotype expression in CD5⁺ and CD5⁻ cord blood B-cells. **Clin Exp Rheumatol 1990; 8 (S-5): 108.**
179. MacGregor AJ, Carthy D, **Mageed R**, Ollier WER, Silman AJ. Lack of concordance for rheumatoid factor positivity in a nationwide study of twins with rheumatoid arthritis. **Br J Rheumatol 1991; 30 (Suppl 2): 58.**
180. **Mageed RA**, Brown CMS, Deane M, Katsikis P, Maini RN. Molecular and serological analysis of the B-lymphocyte repertoire in rheumatoid arthritis synovia. **Clin Rheumatol 1992; 11: 129.**
181. Sadigh S, Scott BB, Andrew E, **Mageed RA**, Maini RN. Antigen induced immunoglobulin isotype switch and somatic mutation in the variable region genes of CD5⁺ B-lymphocytes. **Br J Rheumatol 1992; 26: 187.**
182. **Mageed RA**, Moyes S, Brown CMS, Maini RN. Analysis of the B-lymphocyte repertoire in RA synovia. **Br J Rheumatol 1992; 26: 205.**
183. Scott BB, Sadigh S, Stow W, **Mageed RA**, Andrew EM, Maini RN. Molecular mechanisms resulting in pathogenic anti-mouse red blood cell antibodies (MRBC) in NZB mice. **Arthritis Rheum 1992; 35: S169.**
184. Sadigh S, Scott BB, **Mageed RA**, Andrew EM, Malcolm AD, Maini RN. The molecular and cellular basis of anti-ds DNA antibodies in autoimmune BW mice. **Arthritis Rheum 1992; 35: S169.**



185. Tzioufas AG, Boumba D, **Mageed RA**, Carson DA, Moutsopoulos HM. Prevalence of cross-reactive idiotypes (CRI) of monoclonal rheumatoid factors in Sjogren's syndrome (SS). Relevance of V_HI and V_HIIIb associated CRI with lymphoproliferation of SS. **Clin Rheumatol** 1993; 12: 7.
186. Scott BB, Sadigh S, **Mageed RA**, Andrew EM, Maini RN. Molecular analysis of pathogenic anti-mouse red blood cell antibodies in NZB mice. **Clin Rheumatol** 1993; 12: 8.
187. Katsikis PD, Murison JG, Page TH, **Mageed RA**, Moutsopoulos HM, Feldmann M, Maini RN. CD5⁺ B-lymphocytes and rheumatoid factor associated G6 cross-reactive idiotype in primary Sjogren's syndrome patients. **Clin Rheumatol** 1993; 12: 32.
188. **Mageed RA**, Vencovsky J, Ollier WE, Maini RN. Immunoglobulin variable region gene expression in rheumatoid factors (RF) in homozygotic twins with RA. **Br J Rheumatol** 1993; 32 (suppl 2): 10.
189. Vencovsky J, **Mageed RA**, Ollier WER, Maini RN. Immunoglobulin variable region gene use in monozygotic twins with rheumatoid arthritis. **Clin Rheumatol** 1993; 32: 38.
190. **Mageed RA**, Scott BB, Sadigh S, Andrew EM, Maini RN. Genetic and cellular analysis of haemolytic autoantibody production in NZB mice. **Br J Rheumatol** 1993; 32 (suppl 2): 29.
191. Moyes SP, **Mageed RA**, Brown CM, Maini RN. Genetic analysis of synovial antibody repertoire. **Br J Rheumatol** 1993; 32 (suppl 2): 9.
192. Adebajo AO, **Mageed RA**, Hazleman BL. Rheumatoid factor-associated cross-reactive idiotype (CRI) in patients with tropical infections. **Br J Rheumatol** 1995; 34 (suppl 1): 34.
193. MacGregor AJ, Bamber S, Carthy D, Vencovsky J, **Mageed RA**, Ollier WE, Silman AJ. Heterogeneity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis. **Br J Rheumatol**. 1995; 34(3):215.
194. Burd GB, Maini RN, Mageed RA. Different patterns of cytokine and CD40-ligand expression in spleen germinal centres of NZB/W F1 mice compared with normal CBA mice. **Br J Rheumatol** 1996; 35 (suppl 1): 5.
195. Harmer IJ, **Mageed RA**, Brüggemann M, Mackworth-Young CG. A single anti-DNA-related V_H gene encodes for multiple specificities: the influence of the light chain. **Br J Rheumatol** 1996; 35 (suppl 1): 23.
196. Moyes SP, Mageed RA, Maini RN. Somatic mutation and gene fingerprinting of immunoglobulin lambda light chains in the synovium of patients with rheumatoid arthritis. **Br J Rheumatol** 1996; 35 (suppl 1): 172.
197. Hajeer AH, Iazarus M, Turner D, **Mageed RA**, Vencovsky J, Sinnott P, Hutchinson IV, Ollier WE. 11L-10 promoter region polymorphisms are associated with disease expression in rheumatoid arthritis. **Arthritis Rheum** 1997; 40: S158.
198. Jury EC, Kabouridis PS, Nye KE, **Mageed RA**, Isenberg DA. Diminished Expression of LCK in T Lymphocyte Lipid Rafts from Patients with Systemic Lupus Erythematosus (SLE). **Rheumatology** 2002; 41: 110.



199. Jury EC, Kabouridis PS, Flores-Borja F, **Mageed RA**, Isenberg DA. Abnormal co-localisation of CD45 and lipid rafts is associated with reduced LCK expression in T cells from patients with SLE. **Arthritis Rheum** 2003; **48**: S193.
200. Vencovský J, Zd'árský E, Moyes SP, Hajeer A, Ruzicková Š, Cimburek Z, Ollier WE, Maini RN, **Mageed RA**. Polymorphism in the immunoglobulin VH gene V1-69 affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope. **Rheumatology** 2002; **41**: 401.
201. Jury EC, Kabouridis PS, Flores-Borja F, **Mageed RA**, Isenberg DA. CD45 is abnormally associated with lipid rafts in T lymphocytes from patients with systemic lupus erythematosus. **Rheumatology** 2003; **42**, 5.
202. Williams RO, Ahmed S, Isenberg DA, **Mageed RA**. Deficiency in A-Kinase anchor protein expression in peripheral blood leukocytes from patients with SLE. **Rheumatology** 2003; **42**: 73.
203. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, **Mageed R**. Analysis of lipid raft-associated signalling molecules in B cells from normal and patients with SLE. **Rheumatology** 2003; **42**: 72-73.
204. Jury EC, Kabouridis PS, Flores-Borja F, **Mageed RA**, Isenberg DA. (2004). Altered lipid raft expression and associated signalling in T lymphocytes from patients with systemic lupus erythematosus (SLE). **Rheumatology** 2004; **43**: 24.
205. Flores-Borja F, Kabouridis PS, Jury E, Isenberg DA, **Mageed RA**. Atypical co-localisation of CD45 and Lyn to lipid raft signaling domains correlates with B-lymphocyte hyper responsiveness in patients with lupus. **Rheumatology** 2004; **43**: 108.
206. Flores-Borja F, Kabouridis PS, Jury E, Isenberg DA, **Mageed RA**. Translocation of CD45 to lipid raft signalling domains and abnormal relocation during B-lymphocyte activation in SLE. **Rheumatology** 2005; **44**, I17.
207. Jawad ASM, Mangat M, Perry JD, **Mageed RA**. Anti-TNF α -based therapy in rheumatoid arthritis (RA): Mechanisms of action and possible causes of non-responsiveness. **Rheumatology** 2007; **47**: II37-II38.
208. Mletzko S, Flores-Borja F, Taher T, Isenberg DA, **Mageed RA**. Differential CD45 isoform expression contributes to B-cell hyperactivity in patients with systemic lupus erythematosus (SLE). **British Society for Immunology**, 2007.
209. Mletzko S, Varin MM, Duchene J, Taher T, Warnes G, Jawad AS, Isenberg DA, **RA Mageed**. Altered membrane expression levels of distinct CD45RB isoforms are associated with B cell hyperactivity in systemic lupus erythematosus (SLE). **Immunology** 2008; **125**: 41.
210. Jawad ASM, Taher TE, Rahim A, D'Acquisto F, Gould D, **Mageed RA**. Selective targeting of the canonical or alternative NF- κ B pathway reveals new insights into mechanisms of B-lymphocyte survival and selection. **Rheumatology** 2009; **48**: 130-131.



211. Mletzko S, Taher T, Flores-Borja F, Isenberg DA, **Mageed RA**. Altered expression of CD45 influences B lymphocyte responses in patients with systemic lupus erythematosus (SLE). Keystone Symposia, Lymphocyte Activation and Signaling. **Keystone Symposium, (B3), Utah, Snowbird, USA 2007**.
212. Mletzko S, Varin M, Duchene J, Taher T, Warnes G, Jawad AS, Isenberg DA, **RA Mageed**. Altered membrane CD45 isoform expression and intracellular signaling defects in B cell from patients with systemic lupus erythematosus (SLE). **Rheumatology, 2009; 48: 132**.
213. Nordin NI, D'Acquisto F, Gibbons S, Perrett D, **Mageed RA**. Immune-modulatory effects of compounds isolated from *Zingiber officinale* Roscoe (var. *rubrum* Theilade) on immune mechanisms associated with psoriasis. **Immunology; 2010; 131: 65**.
214. Nordin NI, D'Acquisto F, Gibbons S, Perrett D, **Mageed RA**. Immune-modulatory Effects of Compounds Isolated from *Zingiber officinale* Roscoe (var. *rubrum* Theilade) on Immune Mechanisms Associated with Psoriasis. **Immunology 2010; 131: 65**.
215. Muhammad HA, Chernajovsky Y, Taher TE, Gould DJ, **Mageed RA**. Therapeutic targeting of pathogenic B lymphocytes using antibody-delivered siRNA. **3rd Int Meeting on Gene therapy 2011**.
216. Nordin NI, Cooper D, D'Acquisto F, Gibbons S, Perrett D, **Mageed RA**. Potent anti-inflammatory compounds identified in *Zingiber officinale* Roscoe var. *rubrum* Theilade: Mechanisms of action in psoriasis. **3rd Int Meeting on Gene therapy 2011**.
217. Nordin NI, D'acquisto F, Gibbons S, Perrett D, **Mageed RA**. Potent anti-inflammatory compounds identified in *Zingiber officinale* Roscoe var. *rubrum* Theilade: Mechanisms of action in psoriasis. **Planta Med 2011; 77: PM92**.
218. Muhammad HA, Taher T, Mullen L, Taher TE, Gould DJ, **Mageed RA**. Generation of a secreted scFv for specific delivery of siRNA to B-lymphocytes. **Human Gene Therapy 2013; 24: A36**.
219. Mittal GA, **Mageed RA**, Chernajovsky Y. Human (H161R) IL-17F mutant is a dual antagonist of IL-17A and IL-17F. **Rheumatology 2011; 50: 53**.
220. Bystrom J, Taher T, Al-Bogami M, Kelly S, Mangat P, Jawad A, **Mageed RA**. T lymphocyte cytokines distinguish responder from non-responder rheumatoid arthritis patients treated with anti-tumour necrosis factor alpha agents. **Proceedings of the British Pharmacological Society 2013**.
221. Muhammad H, Taher T, Mullen L, Pastan I, Marshall J, Chernajovsky Y, Gould D, **Mageed R**. Development of a novel approach for targeted delivery of siRNA to B lymphocytes with potential application in cancer. **Hum Gene Ther 2014; 25: A55**.
222. Bystrom J, Taher T, Al-Bogami M, Alzabin S, Kelly S, Mangat P, Williams R, Jawad A, **Mageed R**. Cytokine production identified a subset rheumatoid arthritis patients T lymphocytes that is associated with responsiveness to biologic anti-TNF-alpha agents. **Ann Rheum Dis 2014; 73: 356**.



223. Simon O, Cornec D, **Mageed R**, Pers JO, Hillion S. In-Depth Characterization of CD24(high)CD38(high) Transitional Human B Cells Reveals Different Regulatory Profiles and are Abnormally Distributed in Sjogren's Syndrome. **Scand J Immunol** 2015; **81**: 378.

Link to Scopus <https://www.scopus.com/authid/detail.uri?authorId=7006516084>

Link to Orcid <https://orcid.org/0000-0003-1561-784X>

Link to Publons

Link Academia <https://qmul.academia.edu/RizgarMageed>

Link to google scholar

Others